NEW ORLEANS, LA. (PRWEB) AUGUST 06, 2019 - PRESS RELEASE - Navigator Genomics (NGT) has announced its intention to initiate a Regulation A+ initial public offering (IPO) that allows both accredited and non-accredited investors to participate in the rapidly exploding cannabis industry by investing in what may become the largest repository in the world of HIPAA-compliant DNA database test results.
NGT’s CEO, Travis Parr, a successful venture capitalist, stated, “Over 137 million Americans take multiple pharmaceutical prescription drugs. Over 50 percent of people suffer drug interactions when combining medical cannabis and prescription drugs taken for chronic conditions. Our information on the interaction between cannabinoid compounds and over 416 of the top prescribed medicines have been rigorously sourced from FDA and other scientific sources. We make this drug interaction information available in a clear and easy to understand report that benefits patients, doctors, and large health organizations. Personalized, precision medicine, based on an individual’s DNA, is the future of medicine. Our goal in raising capital is to make our tests more widely available and to more comprehensively cover specific chronic conditions such as Autism, Fibromyalgia, PTSD and the top 20 diseases that afflict so many people in the USA, and around the world."
NGT has chosen to work with Robert Merrill Fletcher, ChE, the founder of The Canna Unicorns, a cannabis-focused, investment banking firm. Fletcher said, “We choose to work with companies that have a focus on both providing both social benefits and the possibility of achieving a $1 billion valuation. Navigator Genomics has both. We look forward to helping NGT become the market leader in the medical cannabis DNA consumer testing space and helping people around the globe.”
Learn more about NGT's Pharmacogenomic Testing for MMJ at https://youtu.be/d7fIjPlwEnU.
